Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zevorcabtagene autoleucel - CARsgen

Drug Profile

Zevorcabtagene autoleucel - CARsgen

Alternative Names: Anti-BCMA CAR T cell therapy - CARsgen; BCMA-redirected autologous T cells-CARsgen; CAR BCMA T-cell therapy-CARsgen; CAR-BCMA T Cell Infusion; CT 053 - CARsgen

Latest Information Update: 25 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CARsgen
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple myeloma

Most Recent Events

  • 23 Mar 2022 CARsgen announces intention make regulatory submissions for marketing approval to the NMPA for multiple myeloma in China in the first half of 2022
  • 23 Mar 2022 CARsgen announces intention to submit BLA for multiple myeloma to the US FDA in 2023
  • 23 Mar 2022 CARsgen completes enrolment in the phase I/II LUMMICAR STUDY 1 trial for Multiple myeloma (Second-line therapy or greater) in China (IV) (NCT03975907)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top